Trial
NCT01041027
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Albert Einstein College of Medicine
Collaborators
National Cancer Institute (NCI)
Condition
Endometrial Adenocarcinoma
Intervention
Paclitaxel
Why stopped
Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-26